Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:07 2024-06-04 EDT			5-day change	1st Jan Change
1.9 ^GBX	+2.70%		-19.15%	-71.64%

05-28	NetScientific backs Wanda; Inspirit Energy wins deal	AN
05-10	Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Proactive research analyst says Shield Therapeutics "in fast growth mode"

February 13, 2023 at 08:33 am

(via NewsDirect)

Proactive research analyst John Savin speaks to Thomas Warner at the London studio after releasing his latest report into commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF).

Savin says that Shield Therapeutics is "in fast growth mode" after its first full year of trading and gives his take on how he expects the company to perform in 2023.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Shield Therapeutics plc

NetScientific backs Wanda; Inspirit Energy wins deal	05-28	AN
Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	05-09	CI
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	04-30	AN
Transcript : Shield Therapeutics plc, 2023 Earnings Call, Apr 30, 2024	04-30
Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024	02-22
FTSE 100 takes hit ahead of FOMC minutes	02-21	AN
Shield Therapeutics sinks as strong performance marred by data issues	02-21	AN
Shield Therapeutics plc Announces Unaudited Sales Results for the Year Ended 31 December 2023	02-21	CI
Shield Therapeutics hires former Akili leader as new CFO	01-09	AN
Shield Therapeutics Names New CFO	01-09	MT
Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024	01-08	CI
Comptoir opens restaurant; Intercede wins contract	12-07	AN
FTSE 100 Ends Higher Fueled by Energy Stocks	23-10-12	DJ
Shield Therapeutics Chief Financial Officer Rudolf to leave	23-10-12	AN
AIM WINNERS & LOSERS: Windward sees high contracting activity levels	23-10-12	AN
Shield Therapeutics CFO to Step Down	23-10-12	MT
Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023	23-10-12	CI
Aston Martin CEO ups stake; Alkemy's lithium deal	23-10-03	AN
Shield Therapeutics completes USD20 million SWK financing	23-10-03	AN
Shield Therapeutics Closes $20 Million Debt Facility with SWK Funding	23-10-03	MT
EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy	23-10-02	AN
Shield Therapeutics Raises $6 Million via Share Issue	23-09-29	MT
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	23-09-28	DJ
Shield Therapeutics completes GBP5 million share placing	23-09-28	AN
Shield Therapeutics raises funds for US sales push as loss narrows	23-09-28	AN

Chart Shield Therapeutics plc

Duration

Period

More charts

Company Profile

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Shield Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.019 GBP

Average target price

0.16 GBP

Spread / Average Target

+742.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHIELD THERAPEUTICS PLC	-71.64%	18.5M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	121B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.82B
ARGENX SE	+1.69%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-40.52%	16.33B
BEIGENE, LTD.	-14.00%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.74B

Bio Therapeutic Drugs